JP2023505303A5 - - Google Patents
Info
- Publication number
- JP2023505303A5 JP2023505303A5 JP2022534242A JP2022534242A JP2023505303A5 JP 2023505303 A5 JP2023505303 A5 JP 2023505303A5 JP 2022534242 A JP2022534242 A JP 2022534242A JP 2022534242 A JP2022534242 A JP 2022534242A JP 2023505303 A5 JP2023505303 A5 JP 2023505303A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- per
- body weight
- agonist
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19214049.9 | 2019-12-06 | ||
| EP19214049 | 2019-12-06 | ||
| PCT/EP2020/084665 WO2021110930A1 (en) | 2019-12-06 | 2020-12-04 | Combination immunotherapy of il-15 and cd40 agonist in cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023505303A JP2023505303A (ja) | 2023-02-08 |
| JP2023505303A5 true JP2023505303A5 (https=) | 2023-11-17 |
Family
ID=68808124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534242A Pending JP2023505303A (ja) | 2019-12-06 | 2020-12-04 | 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220411524A1 (https=) |
| EP (1) | EP4069739A1 (https=) |
| JP (1) | JP2023505303A (https=) |
| CN (1) | CN115052891A (https=) |
| AU (1) | AU2020395907A1 (https=) |
| CA (1) | CA3163777A1 (https=) |
| IL (1) | IL293613A (https=) |
| WO (1) | WO2021110930A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024523181A (ja) * | 2021-06-03 | 2024-06-28 | アペクシジェン アメリカ， インコーポレイテッド | Ｃｄ－４０アゴニストを用いてがんを処置する方法 |
| EP4415757A4 (en) * | 2021-10-15 | 2025-10-08 | Univ Rockefeller | COMBINATION OF ANTI-CD40 ANTIBODIES AND IL-15 FOR THE TREATMENT OF CANCER |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7175838B2 (en) * | 2001-08-23 | 2007-02-13 | The United States Of America Represented By The Department Of Health And Human Services | Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
-
2020
- 2020-12-04 IL IL293613A patent/IL293613A/en unknown
- 2020-12-04 EP EP20824142.2A patent/EP4069739A1/en active Pending
- 2020-12-04 JP JP2022534242A patent/JP2023505303A/ja active Pending
- 2020-12-04 WO PCT/EP2020/084665 patent/WO2021110930A1/en not_active Ceased
- 2020-12-04 US US17/781,583 patent/US20220411524A1/en active Pending
- 2020-12-04 CN CN202080092819.9A patent/CN115052891A/zh active Pending
- 2020-12-04 AU AU2020395907A patent/AU2020395907A1/en active Pending
- 2020-12-04 CA CA3163777A patent/CA3163777A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299376A (en) | Fixed dose combination of pertuzumab plus transtuzumab | |
| JP2012067116A5 (https=) | ||
| CN106562952B (zh) | 氯胺酮在治疗重性抑郁障碍中的应用 | |
| JP2016516016A5 (https=) | ||
| Brown et al. | Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy | |
| JP2016526531A5 (https=) | ||
| JP2011515481A (ja) | 癌の処置のための方法および組成物 | |
| RU2018134167A (ru) | Комбинированная терапия для лечения острого миелоидного лейкоза | |
| RU2015152860A (ru) | Режим введения и составы для аденовирусов типа в | |
| US20100160233A1 (en) | Antitumour combinations containing a vegf inhibiting agent and irinotecan | |
| BR112022009283A2 (pt) | Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina | |
| JP2023505303A5 (https=) | ||
| EP2254570B1 (en) | Combination comprising paclitaxel for treating ovarian cancer | |
| JP2020536121A5 (https=) | ||
| JP2025148449A5 (https=) | ||
| JP7221956B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2019501925A5 (https=) | ||
| CN119326902A (zh) | 癌症联合治疗的组合物与方法 | |
| Zhang et al. | The use of nicardipine for electroconvulsive therapy: a dose-ranging study | |
| Choi et al. | Erythropoiesis-stimulating agents and cancer: myth or truth | |
| CN109966275B (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| Kumar et al. | A randomized, controlled study to compare the effects of intravenous labetalol and esmolol on haemodynamic changes during laryngoscopy and intubation | |
| Shreiber | Erenumab (Aimovig) for migraine prophylaxis in adults | |
| JP2023550043A5 (https=) | ||
| CN120361228B (zh) | 一种葡萄糖激酶激活剂与pi3k抑制剂的组合物 |